Emcure Q3FY26 performance reflected robust growth across both domestic and international markets, with Emcure Pharmaceuticals reporting strong financial results for the quarter ended December 31, 2025.
The company recorded consolidated revenue from operations of ₹2,363 crore, marking a year-on-year growth of 20.4%.
Profit after tax (PAT) for the quarter stood at ₹231 crore, up 48.2% year-on-year, despite an exceptional expense of ₹38 crore related to labour code changes.
EBITDA for the quarter rose 27.2% YoY to ₹460 crore, while EBITDA margins improved to 19.5%.
Also Read: SKF Industrial Q3FY26: ₹8,609.5 Million Revenue Reported in First Quarter Post Demerger
Emcure Q3FY26 Driven by Strong Domestic and International Performance
The Emcure Q3FY26 quarter witnessed solid growth across both domestic and international businesses.
Domestic business sales reached ₹1,025 crore, registering a 15.4% YoY increase, led by strong performance across key therapies, particularly in chronic segments such as cardio and diabeto.
During the quarter, Emcure strengthened its India portfolio with the launch of Poviztra®, a biological injectable form of semaglutide, in partnership with Novo Nordisk.
With Poviztra, a global original innovator product, the company aims to establish a strong presence in the rapidly emerging weight management segment.
International business sales grew 24.5% YoY to ₹1,338 crore, with all geographies reporting healthy performance. The Rest of the World (RoW) segment grew 30.7%, driven by growth in both non-ARV and ARV segments.
Europe continued to see strong traction led by Manx and Amphotericin B rollout, while Canada business recorded a growth of 12.8%.
Emcure Q3FY26: Outpacing Industry Growth
Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said: “Q3 delivered a strong performance, with all our businesses outpacing industry growth. During the period, we strengthened our India portfolio with launch of Poviztra, a biological injectable semaglutide.
Our international business continues to see strong growth led by launch of our differentiated product pipeline. Emcure’s focus remains on improving profitability even as we invest in people, products and processes to drive strong growth.”
He further added:
“We continue to augment our portfolio in all our focus markets through in-house R&D and in-licensing. The Novo Nordisk partnership has given Emcure an early-entry advantage, positioning us well in the fast-growing obesity segment. We remain focused on delivering strong growth along with margin improvement.”
Also Read: Axis Bank Q3FY26 Results: PAT Rises 28% QoQ, Net Profit at ₹6,490 Crore
Emcure Q3FY26 Consolidated Performance
- Revenue from operations: ₹2,363 crore (↑20.4% YoY)
- EBITDA: ₹460 crore (↑27.2% YoY)
- EBITDA margin: 19.47%
- Profit before tax (PBT): ₹314 crore (↑36.5% YoY)
- Profit after tax (PAT): ₹231 crore (↑48.2% YoY)
- Domestic revenue: ₹1,025 crore (↑15.4% YoY)
- International revenue: ₹1,338 crore (↑24.5% YoY)
